March 07, 2018

Compugen Has Licensed Selexis’ Cell Line-Based Protein Expression Platform for the Development of Antibody-Based Therapeutics

Read More
February 26, 2018

Xencor Signs Four Commercial License Agreements with Selexis SA to Advance its Pipeline of XmAb Bispecific Antibody Drug Candidates

Read More
January 17, 2018

Selexis SA Appoints Alberto Garotti as Chief Financial Officer

Read More

Media Downloads